Pfizer : PFE

All Pfizer Articles

1515 Articles

Jon C. Ogg | Dec 30, 2013 at 11:30 AM EST

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

If one firm can create interest around a stock, it is Goldman Sachs. Investors have followed its Conviction Buy List…

Trey Thoelcke | Dec 18, 2013 at 7:00 AM EST

Teva Secures Rights to Launch Generic Viagra

ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020,…

Paul Ausick | Dec 11, 2013 at 4:14 PM EST

The 5 Stocks That Moved the Market on Wednesday

thinkstockDecember 11, 2013: Markets opened lower again on Wednesday morning on another day of relatively light trading and yet more…

Jon C. Ogg | Dec 11, 2013 at 11:00 AM EST

Big Short Interest Changes in High-Yield Dividend Stocks

courtesy of VerizonThe short interest data for the end of November is out, and the results are somewhat surprising when it…

Jon C. Ogg | Dec 7, 2013 at 8:01 AM EST

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

GS.COMIt is that time of year when investors start positioning their portfolios for the year ahead. 24/7 Wall St. reviews…

Jon C. Ogg | Dec 4, 2013 at 11:55 AM EST

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of…

Jon C. Ogg | Dec 3, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, December 3, 2013.…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

Jon C. Ogg | Nov 12, 2013 at 9:00 AM EST

Short Sellers Made Big Changes in High-Yield Dividend Stocks

We have now seen the short interest reports from the October 31 settlement date and have compared them to the…

Paul Ausick | Oct 29, 2013 at 8:00 AM EDT

Pfizer Continues to Shrink

Wikimedia CommonsPfizer Inc. (NYSE: PFE) reported third-quarter 2013 results before markets opened Tuesday morning. The drug maker posted adjusted diluted…

Jon C. Ogg | Oct 28, 2013 at 1:19 PM EDT

Merck Sets Low Earnings Bar for Pfizer

The drug patent cliff for Big Pharma is coming with some continued consequences, and two drug giants with earnings this…

Douglas A. McIntyre | Oct 28, 2013 at 6:46 AM EDT

A New Rise in Global Mergers/Buyouts

courtesy of Verizon WirelessMergers and acquisitions (M&A) sometimes can be an excellent measure of the economy’s financial health. However, since…

Jon C. Ogg | Oct 27, 2013 at 8:38 AM EDT

The 10 Most Important Earnings in the Week Ahead

Jon OggEarnings season is in full swing and this coming week will bring many key earnings reports. This will also…

Jon C. Ogg | Oct 25, 2013 at 8:50 AM EDT

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

We have seen the short interest reports for the October 15 settlement date. It turns out that short sellers have…

Paul Ausick | Oct 10, 2013 at 10:20 AM EDT

High-Yield Dividend Stocks Face Rising Short Interest

ThinkstockShort sellers have increased their bets against the stable high-dividend stocks that are in most Americans’ retirement accounts and mutual…

1 … 70 71 72 73 74 … 101

Pfizer : PFE

All Pfizer Articles

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

Teva Secures Rights to Launch Generic Viagra

The 5 Stocks That Moved the Market on Wednesday

Big Short Interest Changes in High-Yield Dividend Stocks

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Short Sellers Made Big Changes in High-Yield Dividend Stocks

Pfizer Continues to Shrink

Merck Sets Low Earnings Bar for Pfizer

A New Rise in Global Mergers/Buyouts

The 10 Most Important Earnings in the Week Ahead

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

High-Yield Dividend Stocks Face Rising Short Interest

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

Pfizer : PFE

All Pfizer Articles

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

Teva Secures Rights to Launch Generic Viagra

The 5 Stocks That Moved the Market on Wednesday

Big Short Interest Changes in High-Yield Dividend Stocks

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

Meet the Preliminary 2014 Dogs of the Dow: Dividends Galore

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Short Sellers Made Big Changes in High-Yield Dividend Stocks

Pfizer Continues to Shrink

Merck Sets Low Earnings Bar for Pfizer

A New Rise in Global Mergers/Buyouts

The 10 Most Important Earnings in the Week Ahead

Short Sellers Abandoning Bets Against High-Yield Defensive Dividend Stocks

High-Yield Dividend Stocks Face Rising Short Interest

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line